REVIEW

Pathogenesis of Dengue: Dawn of a New Era [version 1; peer review: 3 approved]

Scott B. Halstead

Dengue Vaccine Initiative, International Vaccine Institute, Seoul, South Korea

V1 First published: 25 Nov 2015, 4(F1000 Faculty Rev):1353
<https://doi.org/10.12688/f1000research.7024.1>

Latest published: 25 Nov 2015, 4(F1000 Faculty Rev):1353
<https://doi.org/10.12688/f1000research.7024.1>

Abstract

Dengue virus (DENV) infections of humans were long thought to be self-limited and of low mortality. Beginning in the 1950s, at the time when four different DENVs were discovered, a lethal variant of dengue emerged. Dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) initially observed in Southeast Asia now has spread throughout the world. Two risk factors for DHF/DSS are well-established: severe disease occurs during a second heterotypic DENV infection or during a first DENV infection in infants born to dengue-immune mothers. A large number of hypotheses have been proposed to explain severe dengue disease. As discussed, few of them attempt to explain why severe disease occurs under the two different immunological settings. New experimental evidence has demonstrated that DENV non-structural protein 1 (NS1) is toll-receptor 4 agonist that stimulates primary human myeloid cells to produce the same cytokines observed during the course of severe dengue disease. In addition, NS1 directly damages endothelial cells. These observations have been repeated and extended to an in vivo mouse model. The well-established phenomenon, antibody-dependent enhancement of DENV infection in Fc-receptor-bearing cells, should similarly enhance the production of DENV NS1 in humans, providing a unitary mechanism for severe disease in both immunological settings

Keywords

Dengue virus, hemorrhagic fever, dengue shock syndrome, dengue vascular permeability syndrome, Dengue pathogenesis, viral toxicosis

Open Peer Review

Approval Status

	1	2	3
version 1 25 Nov 2015

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Eng Eong Ooi**, Duke NUS Graduate Medical School, Singapore, Singapore
2. **Wei Kung Wang**, University of Hawaii, Hawaii, USA
3. **Aravinda de Silva**, University of North Carolina School of Medicine, Chapel Hill, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Scott B. Halstead (halsteads@erols.com)

Competing interests: The author declares that he has no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2015 Halstead SB. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Halstead SB. **Pathogenesis of Dengue: Dawn of a New Era [version 1; peer review: 3 approved]**
F1000Research 2015, 4(F1000 Faculty Rev):1353 <https://doi.org/10.12688/f1000research.7024.1>

First published: 25 Nov 2015, 4(F1000 Faculty Rev):1353 <https://doi.org/10.12688/f1000research.7024.1>

Introduction

During the first half of the 20th century, human responses to dengue virus (DENV) infection were described in multiple studies on hundreds of adult volunteers in different parts of the world¹⁻⁹. On the basis of these case descriptions, many earlier 19th and 20th century outbreaks were identified as dengue fever (DF). This large historical experience failed to prepare the scientific community for a surprise in 1956. DENVs were identified as the cause of a fatal hemorrhagic fever in Southeast Asian children with few features of DF^{10,11}. Ever since, the question has been “why did dengue turn deadly?”

In the 1960s, dengue research programs in Southeast Asia found that children were dying of a new clinical syndrome, an acute febrile disease accompanied by a complex of physiologic abnormalities affecting multiple organ systems including the liver, blood coagulation, complement, hematopoiesis, serum proteins, and the vascular system that reach maximal expression at defervescence. Initially, this entity was named the dengue shock syndrome (DSS) and sub-shock, dengue hemorrhagic fever (DHF)¹²⁻¹⁶. However, the disease described in some detail in **Box 1** is best identified as the dengue vascular permeability syndrome (DVPS).

Box 1. DVPS Clinical Presentation

There is an abrupt onset of fever accompanied by malaise, vomiting, headache, anorexia, abdominal pain and upper respiratory symptoms. Two to five days later the patient may rapidly deteriorate and collapse. At or near defervescence, the patient may have cold, clammy extremities, slow venous filling, a warm trunk, flushed face, circumoral and peripheral cyanosis, diaphoresis, restlessness, irritability, mid-epigastric pain, decreased urinary output and hypovolemia. There may be scattered petechiae on the forehead and extremities or spontaneous ecchymoses, bruising and bleeding at sites of venipuncture. Respirations are rapid. The pulse is weak, rapid, and thready and the heart sounds are faint. The liver may enlarge to 4–6 cm below the costal margin and is usually firm and somewhat tender. Laboratory findings during acute stage illness include thrombocytopenia, elevated liver enzymes, activated complement with high levels of C3a and C5a, fibrin split products, low fibrinogen, prolonged bleeding time, prolonged APTT, low serum albumin and elevated hematocrit^{13,17,85,86}.

A critical loss of fluid and smaller macromolecules through damaged endothelium may result in reduced blood volume and an increase in hematocrit. A hematocrit that is 20% or greater than a convalescent value denotes cardiovascular instability. Vascular leakage can be detected directly by x-ray or sonography. Pleural effusions are best detected by lateral view chest x-ray. Abdominal sonograms may detect gall bladder wall thickening and serosal effusions⁸⁷. Approximately 20–30% of cases of DVPS develop shock with an onset that can be subtle, arising in patients who are fully alert, and accompanied by increased peripheral vascular resistance. Shock is not due to congestive heart failure but to hypovolemia. With increasing cardiovascular compromise, diastolic pressure rises towards systolic and pulse pressure narrows to less than 20 mm Hg. Fewer than 10% of patients have gross ecchymosis or gastrointestinal bleeding, usually after a period of uncorrected shock.

After a 24- to 36-hr period of crisis, the vascular leak self-heals and convalescence is fairly rapid and complete. Encephalopathy may be seen during this period. Rare complications are myocarditis and hepatitis. Bradycardia and ventricular extrasystoles are common during convalescence⁸⁷.

Etiological studies discovered that hospitalized DVPS occurs in two immunological settings: 1) approximately 90% with secondary-type DENV antibody responses were shown epidemiologically to accompany a second heterotypic DENV infection, and 2) approximately 5% of cases were infants born to dengue-immune mothers who had primary DENV antibody responses¹⁷⁻¹⁹. Important caveats have been discovered for each of these two immunological risk factors. Hospitalized DVPS accompanying a second heterotypic dengue infection is a rare event. Approximately 2% to 4% of secondary dengue infections resulted in hospitalized DHF/DSS²⁰⁻²³. Young children are inherently at greater risk of developing DVPS during a second heterotypic dengue infection than are older children or adults²⁴. When sequential DENV infections are closely spaced, there is significant cross-protection²⁵. This cross-protection initially prevents infection by a second DENV but it persists in partial form, preventing DVPS as a component of the disease response for at least two years^{26,27}. As the interval between sequential DENV infections increases beyond two years, an ever larger fraction of second heterotypic DENV 2 and 3 infections have culminated in severe DVPS^{28,29}. DVPS in infants usually occurs during the second half of the first year of life. Passive antibodies from mothers, known to have been infected by multiple DENV earlier in life, protect against DENV infections for a period of months, then mediate DVPS and finally disappear at around 12 months^{18,30}. DVPS occurs more frequently during DENV infections of infants with passively acquired DENV antibodies than in older children accompanying a second DENV infection^{30,31}.

In the decades after DHF and DSS were first described, numerous observations have been made in dengue-infected individuals of all ages, and hypotheses have been put forward to explain the mechanism of severe and fatal dengue. Roughly in chronological order, those attracting the most attention are the following:

1. Antigen-antibody-complement-mediated vascular permeability

During a second heterotypic dengue infection, the simultaneous circulation of anamnestic IgG dengue antibodies and dengue viral antigens activates complement via the C3 activator and by initiating the C1, C4, C2 cascade, contributing to a reduced level of C3. The resulting increased levels of C3a and C5a anaphylatoxins are thought to mediate vascular permeability^{14,15,32}.

2. Antibody-dependent enhancement of dengue infection

This phenomenon was discovered when it was observed that DENV readily grew *in vitro* in cultures of peripheral blood monocytes obtained from dengue-immune monkeys or humans but less well in monocytes from non-immunes^{33,34}. Soon after, it was discovered that this phenomenon was readily mediated by dengue antibodies that were diluted above the neutralization endpoint, added to dengue viruses, and grown in cultured monocytes from seronegative donors^{35,36}. In rhesus monkeys, enhanced viremias were observed *in vivo* during secondary compared with primary DENV 2 infections³⁷. Enhanced DENV 2 viremias were also produced in susceptible monkeys sensitized with a small intravenous dose of dengue-immune human cord blood serum³⁸.

3. Exaggerated T-cell response

Vascular permeability has been attributed to cytokines, such as interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNFα),

released by cohorts of overactive T cells that accompany immune responses during a second heterotypic DENV infection^{39,40}.

4. Virulent dengue viruses

The concept of “virulent” or “non-virulent” dengue viruses developed when it was observed that the American genotype of DENV 2 did not produce a large outbreak of DHF/DSS in Iquitos, Peru, during a 1995 outbreak in a population that was highly immune to DENV 1^{41,42}. Also, pronounced differences in clinical expression of infections caused by a genotype of DENV 2 were observed in outbreaks on different Pacific islands⁴³.

5. Heterophile immunity

In the extensive experimental literature describing observations in mouse models, it is proposed that DVPS is a short-lived autoimmune disease resulting from destructive tissue responses to pathogenic antibodies raised to DENV NS1 proteins. These antibodies cross-react with host endothelial cells, blood-clotting proteins, and liver cells. Mimetic antibodies are thought to reach pathological levels during secondary DENV infections^{44–46}.

6. Infection-ending T-cell responses misdirected by original antigenic sin

Analysis of the functional phenotypes of CD8⁺ T cells in DHF cases revealed that recognition between different DENV peptides was associated with reduced cytolytic potential without reducing cytokine production^{47–49}. Activation of both CD4⁺ and CD8⁺ T cells with peptide variants induced different sets of cytokines⁵⁰. Pathogenic heterologous T-cell responses or selectively defective T-cell responses (original antigenic sin) result in cytokines and chemokines (“cytokine storm”) that produce vascular permeability leading to DHF/DSS. T-cell responses enhance the severity of DENV infections by an *in vitro* process that has not been demonstrated *in vivo*^{47,51–53}.

7. Direct infection of myeloid cells

A host of *in vitro* studies suggest that vascular permeability results from cytokines or other factors generated by DENV infection of myeloid cells, including mast cells^{54–59}.

8. Direct infection of endothelial cells

Dengue viruses readily grow in primary human endothelial cell explants, generating products that increase vascular permeability⁶⁰. Transcriptional activity, protein production, and cell surface protein expression by endothelial cells are significantly altered by DENV infection *in vitro*. Several pathways identified in DHF/DSS, including inflammation, apoptosis, and coagulation, are affected^{61,62}. Apoptosis of endothelial cells has been demonstrated in mice and has been proposed to be the mechanism of vascular leakage⁶³.

Which is the more relevant pathogenic mechanism?

Only one of these hypotheses satisfies the requirement of “Occam’s razor” (among competing hypotheses, the one with the fewest assumptions should be selected), providing a hypothesis that offers the simplest explanation why DVPS occurs in persons who are actively or passively dengue-immune. One hypothesis, antibody-dependent enhancement of dengue infection (ADE) (#2), satisfies this requirement, whereas hypotheses #1 (acute immune complex

disease), #3 (exaggerated T-cell response), #5 (heterophile immunity), and #6 (original antigenic sin) do not. These hypotheses are unable to explain why DVPS accompanies a primary DENV infection in infants who circulate passively acquired dengue antibodies. Hypothesis #4 (virulent DENV) suggests that it is the innate properties of different genotypes or strains of dengue viruses that control the outcome of disease. DVPS, carefully documented, has not accompanied DENV infections in naïve populations. Dengue viral contributions to DVPS are conditioned by pre-illness dengue antibodies. This is not to say that differences between DENV strains or genotypes may not interact with antibodies to profoundly change biological outcomes. This important possibility is partially discussed at greater length elsewhere^{64,65}. This pathogenesis-relevant antibody-dependent phenomenon is best described as “fitness” and not as “virulence”. Hypothesis #7, when confined to experimental studies on the implications of direct infection, predicts that any DENV infection, regardless of immunological status, may result in DVPS. Hypothesis #8 attributes DVPS to the direct viral infection of endothelial cells. The problem here is the paucity of high-quality studies. The reagents needed to identify sites of DENV replication in human autopsy tissues are scarce, present difficult quality-control challenges, and are not standardized throughout the dengue research community. In studies using anti-NS3 staining, DENV antigens have been localized to focal endothelial cells in several organs. But the distribution and intensity of staining is unlike that observed with the direct infection of endothelial cells in hantaviral pulmonary syndrome associated with severe localized vascular permeability^{66–68}. A recent effort made to identify endothelial cells stained with DENV antigens was negative⁶⁹.

Dengue pathogenesis: ADE and dengue viral toxicosis

All infectious diseases are kinetic, consisting of the invasion of the microorganism (afferent phase) followed by the host response (efferent phase), including disease and elimination of the organism. The setting of DENV infections is unique in that pre-infection events may control afferent phenomena. During the afferent phase of dengue infections, DENV infectious immune complexes regulate infection of Fc-receptor-bearing cells. Antibodies, whether passively or actively acquired, on some, but not all occasions, intervene with infection dynamics to produce an expanded infected cell mass. As predicted by experimental ADE studies, early acute-phase illness sera from children with second DENV infections were found to have higher peak viremia and antigenemia titers prior to the onset of DHF/DSS than did similarly timed sera from children who developed a milder illness^{70–72}. More recently, Vietnamese and Sri Lankan researchers observed the circulation of NS1 at higher titers and longer intervals during severe disease^{73,74}. Afferent ADE has been successfully modeled *in vivo*. DENV 2, 3, and 4 infections in type I and II interferon receptor-deficient mice produce a non-paralytic lethal disease accompanied by many features of DVPS, high levels of virus in tissues and circulating in blood and efferent phenomena, a cytokine storm, low platelet counts, elevated hematocrit, increased vascular permeability, and intestinal hemorrhage^{75–77}. Mice transfused with enhancing concentrations of dengue antibodies prior to infection with a sub-lethal dose of mouse-adapted DENV 2 developed lethal vascular permeability with TNF release^{78,79}. It is now known that dengue immune complex infection of human monocytes/macrophages boosts DENV replication

approximately 100-fold in association with the suppression of type I interferon or increased production of IL-10 or both. This phenomenon is called intrinsic ADE (iADE)^{80,81}. Infectious immune complexes also achieve a threefold infection advantage in FcR-bearing cells compared with DENV alone (extrinsic ADE– eADE)⁸².

What causes the efferent signs and symptoms of DVPS? Missing is the “smoking gun” that produces liver injury, vascular permeability, activation of complement, and alteration of hemostasis. Very recently, Paul Young’s group observed an analogy between the cellular biology of bacterial lipopolysaccharides (LPS) and that of DENV NS1⁸³. Each of these compounds interacts with Toll-like receptor 4 (TLR 4) on the surface of monocytes, macrophages, and endothelial cells, inducing the release of a range of cytokines and chemokines. These are the same mediators identified in the blood of patients with DHF/DSS. *In vitro*, NS1 resulted in the disruption of endothelial cell monolayer integrity. The authors conclude that DSS may be a viral protein toxicosis. NS1-mediated cytokine release was inhibited by the TLR4 antagonist LPS-*Rhodobacter sphaeroides*, suggesting an avenue for therapeutic intervention. Crucially, this same observation has been confirmed in an *in vivo* model. The Harris laboratory has shown that DENV 2 NS1 inoculated intravenously at physiologically relevant concentrations in sub-lethal DENV 2-infected IFNAR^{-/-}C57BL/6 mice produced lethal vascular permeability⁸⁴. *In vitro*, NS1, when added to cultured endothelial

cells, resulted in endothelial permeability. Vaccination of mice with DENV 2 NS1 protected against endothelial leakage and death due to lethal DENV 2 challenge. Mice immunized with DENV 2 NS1 protein were completely protected against homologous DENV 2 challenge, and immunization with DENV 1, 3, and 4 NS1 proteins partially protected against heterologous DENV 2 challenge.

DENV NS1 blood levels and therefore NS1 toxicosis are efferent mechanisms directly controlled by ADE. It is not clear yet whether NS1 alone, NS1-induced cytokines, virus replication-induced damage, or activated complement is responsible for the *in vivo* efferent DVPS phenomenon. There is a delay of several days between the early occurrence of peak blood levels of NS1 and defervescence-associated organ pathology. This is not fully understood. It is clear, however, that DENV NS1 toxicosis introduces a new era to dengue pathogenesis research.

Competing interests

The author declares that he has no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Cleland JB, Bradley B, McDonald W: **On the Transmission of Australian Dengue by the Mosquito *Stegomyia fasciata***. *Med J Aust*. 1916; 2(10): 179–184.
[Reference Source](#)
- Chandler AG, Rice L: **Observations on the etiology of dengue fever**. *Am J Trop Med Hyg*. 1923; s1–3(3): 233–262.
[Reference Source](#)
- Siler JF, Hall MW, Hitchens AP: **Dengue: Its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention**. *The Philippine Journal of Science*. 1926; 29: 1–304.
- Simmons JS, St John JH, Reynolds FHK: **Experimental Studies of Dengue**. *Philipp J Sci*. 1931; 44(1–2): 1–252.
[Reference Source](#)
- Snijders EP, Dinger EJ, Schuffner WAP: **On the transmission of dengue in Sumatra**. *Am J Trop Med Hyg*. 1931; s1–11(3): 171–197.
[Reference Source](#)
- Sabin AB, Schlesinger RW: **Production of immunity to dengue with virus modified by propagation in mice**. *Science*. 1945; 101(2634): 640–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kimura R, Hotta S: **On the inoculation of dengue virus into mice**. *Nippon Igaku*. 1944; 3379: 629–633.
- Dorrance WR, Frankel JW, Gordon I, et al.: **Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses**. *J Immunol*. 1956; 77(5): 352–64.
[PubMed Abstract](#)
- Wisseman CL Jr, Sweet BH, Rosenzweig EC, et al.: **Attenuated Living Type 1 Dengue Vaccines**. *Am J Trop Med Hyg*. 1963; 12: 620–623.
[Reference Source](#)
- Quintos FN, Lim LE: **Philippine hemorrhagic fever**. *St Tomas J Med*. 1956; 11: 319–328.
- Hammon WM, Rudnick A, Sather GE: **Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand**. *Science*. 1960; 131(3407): 1102–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Cohen SN, Halstead SB: **Shock associated with dengue infection. I. Clinical and physiologic manifestations of dengue hemorrhagic fever in Thailand, 1964**. *J Pediatr*. 1966; 68(3): 448–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Weiss HJ, Halstead SB: **Studies of hemostasis in Thai hemorrhagic fever**. *J Pediatr*. 1965; 66(5): 918–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pathogenetic mechanisms in dengue haemorrhagic fever: report of an international collaborative study**. *Bull World Health Organ*. 1973; 48(1): 117–33.
[PubMed Abstract](#) | [Free Full Text](#)
- Bokisch VA, Top FH Jr, Russell PK, et al.: **The potential pathogenic role of complement in dengue hemorrhagic shock syndrome**. *N Engl J Med*. 1973; 289(19): 996–1000.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Halstead SB, Cohen SN: **Dengue Hemorrhagic Fever at 60 Years: Early Evolution of Concepts of Causation and Treatment**. *Microbiol Mol Biol Rev*. 2015; 79(3): 281–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Nimmannitya S, Halstead SB, Cohen SN, et al.: **Dengue and chikungunya virus infection in man in Thailand, 1962–1964. I. Observations on hospitalized patients with hemorrhagic fever**. *Am J Trop Med Hyg*. 1969; 18(6): 954–71.
[PubMed Abstract](#)
- Halstead SB, Nimmannitya S, Cohen SN: **Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered**. *Yale J Biol Med*. 1970; 42(5): 311–28.
[PubMed Abstract](#) | [Free Full Text](#)
- Halstead SB, Nimmannitya S, Yamarat C, et al.: **Hemorrhagic fever in Thailand; recent knowledge regarding etiology**. *Jpn J Med Sci Biol*. 1967; 20(Suppl): 96–103.
[PubMed Abstract](#)
- Halstead SB, Scanlon JE, Umpaivit P, et al.: **Dengue and chikungunya virus infection in man in Thailand, 1962–1964. IV. Epidemiologic studies in the Bangkok metropolitan area**. *Am J Trop Med Hyg*. 1969; 18(6): 997–1021.
[PubMed Abstract](#)
- Russell PK, Yuill TM, Nisalak A, et al.: **An insular outbreak of dengue hemorrhagic fever. II. Virologic and serologic studies**. *Am J Trop Med Hyg*. 1968; 17(4): 600–8.
[PubMed Abstract](#)

22. Winter PE, Yuill TM, Udomsakdi S, *et al.*: **An insular outbreak of dengue hemorrhagic fever. I. Epidemiologic observations.** *Am J Trop Med Hyg.* 1968; 17(4): 590–9.
[PubMed Abstract](#)
23. Winter PE, Nantapanich S, Nisalak A, *et al.*: **Recurrence of epidemic dengue hemorrhagic fever in an insular setting.** *Am J Trop Med Hyg.* 1969; 18(4): 573–9.
[PubMed Abstract](#)
24. **F** Guzmán MG, Kouri G, Bravo J, *et al.*: **Effect of age on outcome of secondary dengue 2 infections.** *Int J Infect Dis.* 2002; 6(2): 118–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
25. Sabin AB: **Research on dengue during World War II.** *Am J Trop Med Hyg.* 1952; 1(1): 30–50.
[PubMed Abstract](#)
26. **F** Anderson KB, Gibbons RV, Cummings DA, *et al.*: **A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand.** *J Infect Dis.* 2014; 209(3): 360–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
27. Montoya M, Gresh L, Mercado JC, *et al.*: **Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year.** *PLoS Negl Trop Dis.* 2013; 7(8): e2357.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Guzmán MG, Kouri G, Valdes L, *et al.*: **Epidemiologic studies on Dengue in Santiago de Cuba, 1997.** *Am J Epidemiol.* 2000; 152(9): 793–9; discussion 804.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Alvarez M, Rodriguez-Roche R, Bernardo L, *et al.*: **Dengue hemorrhagic Fever caused by sequential dengue 1–3 virus infections over a long time interval: Havana epidemic, 2001–2002.** *Am J Trop Med Hyg.* 2006; 75(6): 1113–7.
[PubMed Abstract](#)
30. Halstead SB: **Neutralization and antibody-dependent enhancement of dengue viruses.** *Adv Virus Res.* 2003; 60: 421–67.
[PubMed Abstract](#)
31. Halstead SB: **In the togaviruses, biology, structure, replication.** R. W. Schlesinger, Ed. (Academic Press, New York, 1980), 107–173.
32. Russell P, Brandt W: **Immunopathologic Processes and Viral Antigens Associated with Sequential Dengue Virus Infections.** *Persistent Virus Infections Perspectives in Virology.* 1973; 8: 263–277.
33. Halstead SB, Chow JS, Marchette NJ: **Immunological enhancement of dengue virus replication.** *Nat New Biol.* 1973; 243(122): 24–6.
[PubMed Abstract](#)
34. Halstead SB, Marchette NJ, Sung Chow JS, *et al.*: **Dengue virus replication enhancement in peripheral blood leukocytes from immune human beings.** *Proc Soc Exp Biol Med.* 1976; 151(1): 136–139.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Halstead SB, O'Rourke EJ: **Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody.** *J Exp Med.* 1977; 146(1): 201–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Halstead SB, O'Rourke EJ, Allison AC: **Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting *in vitro* infection.** *J Exp Med.* 1977; 146(1): 218–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Halstead SB, Shotwell H, Casals J: **Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection.** *J Infect Dis.* 1973; 128(1): 15–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Halstead SB: ***In vivo* enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody.** *J Infect Dis.* 1979; 140(4): 527–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Mathew A, Kurane I, Green S, *et al.*: **Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection.** *J Virol.* 1998; 72(5): 3999–4004.
[PubMed Abstract](#)
40. Rothman AL, Ennis FA: **Immunopathogenesis of Dengue hemorrhagic fever.** *Virology.* 1999; 257: 1–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Rico-Hesse R, Harrison LM, Salas RA, *et al.*: **Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas.** *Virology.* 1997; 230(2): 244–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Rico-Hesse R: **Microevolution and virulence of dengue viruses.** *Adv Virus Res.* 2003; 59: 315–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Steel A, Gubler DJ, Bennett SN: **Natural attenuation of dengue virus type-2 after a series of island outbreaks: a retrospective phylogenetic study of events in the South Pacific three decades ago.** *Virology.* 2010; 405(2): 505–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Falconar AK: **The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis.** *Arch Virol.* 1997; 142(5): 897–916.
[PubMed Abstract](#)
45. Lin YS, Yeh TM, Lin CF, *et al.*: **Molecular mimicry between virus and host and its implications for dengue disease pathogenesis.** *Exp Biol Med (Maywood).* 2011; 236(5): 515–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Wan SW, Lin CF, Yeh TM, *et al.*: **Autoimmunity in dengue pathogenesis.** *J Formos Med Assoc.* 2013; 112(1): 3–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Mongkolsapaya J, Dejnirattisai W, Xu XN, *et al.*: **Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.** *Nat Med.* 2003; 9(7): 921–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, *et al.*: **T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?** *J Immunol.* 2006; 176(6): 3821–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Dong T, Moran E, Vinh Chau N, *et al.*: **High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection.** *PLoS One.* 2007; 2(12): e1192.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Mangada MM, Rothman AL: **Altered cytokine responses of dengue-specific CD4⁺ T cells to heterologous serotypes.** *J Immunol.* 2005; 175(4): 2676–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Rothman AL: **Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis.** *Curr Top Microbiol Immunol.* 2010; 338: 83–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Pang T, Cardoso MJ, Guzman MG: **Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS).** *Immunol Cell Biol.* 2007; 85(1): 43–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Rothman AL: **Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.** *Nat Rev Immunol.* 2011; 11(8): 532–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Carr JM, Hocking H, Bunting K, *et al.*: **Supernatants from dengue virus type-2 infected macrophages induce permeability changes in endothelial cell monolayers.** *J Med Virol.* 2003; 69(4): 521–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. **F** Luplertlop N, Missé D, Bray D, *et al.*: **Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction.** *EMBO Rep.* 2006; 7(11): 1176–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
56. Luplertlop N, Missé D: **MMP cellular responses to dengue virus infection-induced vascular leakage.** *Jpn J Infect Dis.* 2008; 61(4): 298–301.
[PubMed Abstract](#)
57. Dejnirattisai W, Duangchinda T, Lin CL, *et al.*: **A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections.** *J Immunol.* 2008; 181(9): 5865–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Michels M, Djamiatun K, Faradz SM, *et al.*: **High plasma mid-regional pro-adrenomedullin levels in children with severe dengue virus infections.** *J Clin Virol.* 2011; 50(1): 8–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. **F** St John AL, Rathore AP, Raghavan B, *et al.*: **Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage.** *Elife.* 2013; 2: e00481.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
60. Srikiatkachorn A: **Plasma leakage in dengue haemorrhagic fever.** *Thromb Haemost.* 2009; 102(6): 1042–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Avirutnan P, Malasit P, Seliger B, *et al.*: **Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis.** *J Immunol.* 1998; 161(11): 6338–46.
[PubMed Abstract](#)
62. Huang YH, Lei HY, Liu HS, *et al.*: **Dengue virus infects human endothelial cells and induces IL-6 and IL-8 production.** *Am J Trop Med Hyg.* 2000; 63(1–2): 71–5.
[PubMed Abstract](#)
63. Chen H, Hofman FM, Kung JT, *et al.*: **Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage.** *J Virol.* 2007; 81(11): 5518–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Halstead SB: **In Clinical Insights: Dengue fever: transmission, diagnosis & surveillance.** J Whitehorn, J Farrar, Eds. Future Medicine, London, 2014; 84–101.
65. Halstead SB: **Dengue Antibody-Dependent Enhancement: Knowns and Unknowns.** *Microbiol Spectr.* 2014; 2(6).
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Balsitis SJ, Coloma J, Castro G, *et al.*: **Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining.** *Am J Trop Med Hyg.* 2009; 80(3): 416–24.
[PubMed Abstract](#)
67. Póvoa TF, Alves AM, Oliveira CA, *et al.*: **The pathology of severe dengue in multiple organs of human fatal cases: histopathology, ultrastructure and virus replication.** *PLoS One.* 2014; 9(4): e83386.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

68. Srikiatkachorn A, Spiropoulou CF: **Vascular events in viral hemorrhagic fevers: a comparative study of dengue and hantaviruses.** *Cell Tissue Res.* 2014; **355**(3): 621–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Aye KS, Charnkaew K, Win N, *et al.*: **Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar.** *Hum Pathol.* 2014; **45**(6): 1221–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Vaughn DW, Green S, Kalayanaraj S, *et al.*: **Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.** *J Infect Dis.* 2000; **181**(1): 2–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Libraty DH, Endy TP, Hough HH, *et al.*: **Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.** *J Infect Dis.* 2002; **185**(9): 1213–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Libraty DH, Young PR, Pickering D, *et al.*: **High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever.** *J Infect Dis.* 2002; **186**(8): 1165–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. Paranavithane SA, Gomes L, Kamaladasa A, *et al.*: **Dengue NS1 antigen as a marker of severe clinical disease.** *BMC Infect Dis.* 2014; **14**: 570.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Tricou V, Minh NN, Farrar J, *et al.*: **Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue.** *PLoS Negl Trop Dis.* 2011; **5**(9): e1309.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Shrestha S, Sharar KL, Prigozhin DM, *et al.*: **Murine model for dengue virus-induced lethal disease with increased vascular permeability.** *J Virol.* 2006; **80**(20): 10208–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
76. Sarathy VV, White M, Li L, *et al.*: **A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease.** *J Virol.* 2015; **89**(2): 1254–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Milligan GN, Sarathy VV, Infante E, *et al.*: **A Dengue Virus Type 4 Model of Disseminated Lethal Infection in AG129 Mice.** *PLoS One.* 2015; **10**(5): e0125476.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Zellweger RM, Prestwood TR, Shrestha S: **Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease.** *Cell Host Microbe.* 2010; **7**(2): 128–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
79. Balsitis SJ, Williams KL, Lachica R, *et al.*: **Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.** *PLoS Pathog.* 2010; **6**(2): e1000790.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
80. Chareonsirisuthigul T, Kalayanaraj S, Ubol S: **Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells.** *J Gen Virol.* 2007; **88**(Pt 2): 365–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
81. Halstead SB, Mahalingam S, Marovich MA, *et al.*: **Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.** *Lancet Infect Dis.* 2010; **10**(10): 712–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Boonnak K, Dambach KM, Donofrio GC, *et al.*: **Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection.** *J Virol.* 2011; **85**(4): 1671–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
83. Modhiran N, Watterson D, Muller DA, *et al.*: **Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity.** *Sci Transl Med.* 2015; **7**(304): 304ra142.
[PubMed Abstract](#) | [Publisher Full Text](#)
84. Beatty PR, Puerta-Guardo H, Killingbeck SS, *et al.*: **Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination.** *Sci Transl Med.* 2015; **7**(304): 304ra141.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Wills BA, Oragui EE, Stephens AC, *et al.*: **Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome.** *Clin Infect Dis.* 2002; **35**(3): 277–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
86. Trung DT, Thao le TT, Hien TT, *et al.*: **Liver involvement associated with dengue infection in adults in Vietnam.** *Am J Trop Med Hyg.* 2010; **83**(4): 774–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. **Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition.** World Health Organization, Geneva, 2009.
[PubMed Abstract](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Aravinda de Silva**

Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA

Competing Interests: No competing interests were disclosed.

2. **Wei Kung Wang**

Department of tropical medicine, University of Hawaii, Hawaii, USA

Competing Interests: No competing interests were disclosed.

3. **Eng Eong Ooi**

Emerging Infectious Diseases Program, Duke NUS Graduate Medical School, Singapore, Singapore

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research